Next Article in Journal
A Mechanistic Review on How Berberine Use Combats Diabetes and Related Complications: Molecular, Cellular, and Metabolic Effects
Previous Article in Journal
Dual Role of Vitamin C-Encapsulated Liposomal Berberine in Effective Colon Anticancer Immunotherapy
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 17
Issue 1
10.3390/ph17010006
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Sinomenium acutum Modulates Platelet Aggregation and Thrombus Formation by Regulating the Glycoprotein VI-Mediated Signalosome in Mice

by
Yeon-Ji Kim
1,
Tae In Kim
1,
Ami Lee
2,3,
Kyungho Kim
1,3,* and
Youn-Hwan Hwang
2,3,*
1
Korean Medicine-Application Center, Korea Institute of Oriental Medicine, Daegu 41062, Republic of Korea
2
Herbal Medicine Research Division, Korea Institution of Oriental Medicine, Daejeon 34054, Republic of Korea
3
Korean Convergence Medical Science Major, KIOM School, University of Science & Technology (UST), Daejeon 34054, Republic of Korea
*
Authors to whom correspondence should be addressed.
Pharmaceuticals 2024, 17(1), 6; https://doi.org/10.3390/ph17010006
Submission received: 6 November 2023 / Revised: 12 December 2023 / Accepted: 18 December 2023 / Published: 20 December 2023
(This article belongs to the Section Natural Products)
Browse Figures
Versions Notes

Abstract

:
Sinomenium acutum (SA) has long been used as a traditional medicine in China, Japan, and Korea to treat a wide range of diseases. It has been traditionally used to ameliorate inflammation and improve blood circulation. However, its role in platelet activation has not been thoroughly investigated. Hence, we conducted this study to assess the potential inhibitory effect of SA on platelet aggregation and thrombus formation. The antiplatelet activities of SA were evaluated by assessing platelet aggregation, granular secretion, intracellular Ca2+ mobilization, and the Glycoprotein (GP) VI-mediated signalosome. The thrombosis and bleeding time assays were used to investigate the effect of SA (orally administered at 50 and 100 mg/kg for seven days) in mice. SA treatment at concentrations of 50, 100, and 200 μg/mL significantly reduced GPVI-mediated platelet aggregation, granular secretion, and intracellular Ca2+ mobilization. Further biochemical studies revealed that SA inhibited spleen tyrosine kinase, phospholipase Cγ2, phosphatidylinositol 3-kinase, and AKT phosphorylation. Interestingly, oral administration of SA efficiently ameliorated FeCl3-induced arterial thrombus formation without prolonging the tail bleeding time. These findings suggest that SA has beneficial effects in thrombosis and hemostasis. Therefore, SA holds promise as an effective therapeutic agent for the treatment of thrombotic diseases.

1. Introduction

Platelets are small, anucleate cell fragments that are essential for blood clotting and preventing bleeding from injuries. Unwanted platelet activation, however, is a significant contributor to the development and progression of cardiovascular disease. Once activated, platelets rapidly adhere to immobilized adhesive proteins such as von Willebrand factor and collagen, triggering platelet activation and aggregation, leading to the formation of platelet-rich thrombi. These thrombi can obstruct arteries and reduce arterial blood flow, thereby causing various diseases, including hypertension, lower-extremity deep venous thrombosis, atrial fibrillation, infective endocarditis, and heart failure [1,2].
Glycoprotein VI (GPVI) is a crucial platelet surface receptor involved in platelet function and activation. When platelets come into contact with exposed collagen, which is found in damaged blood vessel walls, a signaling cascade is initiated, resulting in platelet activation and aggregation. GPVI binds to collagen, recruits, and associates with another platelet receptor known as Fc receptor γ-chain [3]. The FcRγ-chain is essential for GPVI signaling and is also required for the expression of GPVI on the platelet surface. When GPVI forms a dimer, Src family kinases such as Fyn and Lyn phosphorylate the tyrosine residue of the FcRγ on its motif. This subsequently initiates a spleen tyrosine kinase (Syk)-dependent signaling cascade, leading to the recruitment of the linker of activated T cells (LAT) signalosome involving phospholipase C (PLC) γ2 and phosphoinositide-3 kinase (PI3K) [4,5,6]. The tyrosine phosphorylation-based activation of PLCγ2 eventually leads to intracellular Ca2+ accumulation, resulting in platelet activation, the release of granules, shape change, and the formation of platelet aggregates [7,8]. The activation of GPVI-mediated platelet function also triggers the release of various soluble factors, such as adenosine diphosphate (ADP) and thromboxane A2, which further enhance platelet activation and aggregation [3]. Dysfunction or abnormalities in GPVI signaling profoundly affect platelet function and hemostasis. For instance, defects in GPVI signaling pathways can lead to bleeding disorders, while excessive or inappropriate GPVI activation can contribute to thrombotic conditions such as arterial thrombosis [9]. Ongoing research on GPVI and its role in platelet function has identified the GPVI signaling pathway as a pivotal focus in the development of antiplatelet drugs.
Sinomenium acutum (Thumb.) Rehd. et Wils. (Menispermaceae, SA) has long been used as a traditional medicine in China, Japan, and Korea for the treatment of various diseases. It contains an alkaloid called sinomenine, which has received significant research attention for its potential anti-inflammatory, immunosuppressive, and analgesic properties [10,11]. As a result, SA has been used to alleviate pain and reduce inflammation associated with conditions like arthritis, rheumatism, and joint disorders. Furthermore, it has been used to treat fever, skin rashes, and digestive disorders [10,11]. However, the scientific information on SA remains unclear. Therefore, we conducted this study to evaluate the antiplatelet effect of SA on the process of thrombotic diseases using platelet aggregation and platelet-thrombus formation models.
The present study has demonstrated that the ethanol extract of SA has the ability to inhibit thrombus formation in vivo and in vitro, particularly by inhibiting platelet activation and aggregation induced by collagen and collagen-related peptide (CRP). In a mouse model of ferric chloride (FeCl3)-induced thrombosis, SA has been found to play a crucial role in collagen-induced platelet-thrombus formation. Notably, the administration of SA did not significantly increase the tail bleeding time compared to the control mice. These findings highlight the potential of SA to exert antiplatelet and antithrombotic effects without affecting hemostasis. Hence, SA holds great promise as an effective therapeutic agent for the treatment of thrombotic diseases.

2. Results

2.1. SA Suppresses GPVI-Activated Platelet Aggregation and ATP Secretion

To investigate the role of SA in regulating platelet function, platelet aggregation was first assessed. Our findings revealed that stimulation with various agonists, including collagen (1 µg/mL), CRP (0.5 μg/mL), thrombin (0.05 U/mL), U46619 (3 µM), and ADP (2.5 µM), significantly elevated platelet aggregation (Figure 1). However, compared to the vehicle control, SA-treated platelets showed less aggregation stimulated by collagen (≤1 μg/mL) and CRP (≤0.5 μg/mL) (Figure 1A,B). In contrast, thrombin (≤0.05 U/mL), U46619 (≤3 µM), and ADP (≤2.5 µM) did not elicit such an effect (Figure 1C–E). Furthermore, higher concentrations of collagen (≥3 µg/mL) and CRP (≥2 µg/mL) invalidated the observed defects in SA-treated platelets (Figure S1). To further estimate the effect of SA on platelet function, ATP secretion was assessed. Our findings demonstrated that SA treatment at concentrations of 50, 100, and 200 µg/mL caused a significant decrease in ATP secretion facilitated by collagen (≤1 μg/mL) and CRP (≤0.5 μg/mL) compared to the vehicle control (Figure 1A,B). However, stimulation with thrombin (0.05 U/mL) or U46619 (3 µM) did not yield comparable results (Figure 1C,D). The effect of SA on platelet activation using PRP was also investigated in comparison with that in washed platelets. We observed that collagen (1 µg/mL)- or CRP (1 µg/mL)-stimulated platelet aggregation in PRP was diminished by SA in a concentration-dependent manner similar to the effects of washing platelets (Figure 1F,G). These results suggest that plasma proteins do not influence the effects of SA on platelet aggregation. These findings suggest that SA plays an important role in GPVI-mediated platelet aggregation and ATP secretion.

2.2. SA Is Actively Involved in P-Selectin Exposure, αIIbβ3 Integrin Activation, and Ca2+ Mobilization after CRP Induction

To evaluate the effects of SA on platelet activation, P-selectin exposure and αIIbβ3 integrin activation, which are key processes in the positive feedback cycle of platelet activation, were assessed. In a dose-dependent manner, SA at concentrations of 50, 100, and 200 µg/mL significantly reduced P-selectin exposure and lowered αIIbβ3 integrin activation upon CRP (0.5 μg/mL) stimulation (Figure 2A,B). These findings indicate that SA effectively inhibits GPVI-mediated platelet granular secretion and αIIbβ3 integrin activation. Next, we examined the mechanism explaining the association between SA treatment and platelet activation, along with the GPVI-stimulated increase in intracellular Ca2+. Increases in intracellular Ca2+ arise through either Ca2+ release from intracellular Ca2+ stores or influx across the plasma membrane [12]. Our findings demonstrated a significant increase in intracellular Ca2+ release and inflow upon stimulation with CRP (0.5 μg/mL). Moreover, when platelets were pretreated with SA (50, 100, and 200 µg/mL) prior to CRP stimulation, Ca2+ mobilization was inhibited in a dose-dependent manner (Figure 2C). These findings indicate that SA can modulate CRP-triggered intracellular Ca2+ release and influx.

2.3. SA Is Essential in Regulating Syk, PLCγ2, PI3K, AKT, and ERK Phosphorylation Following CRP Activation

The reaction to GPVI-specific agonists involves a substantial enhancement of Ca2+ signaling through the phosphorylation of Syk, PLCγ2, and PI3K signaling molecules [13], which, in turn, monitors platelet activation. Since SA treatment is important for the following Ca2+ mobilization, the effect of SA treatment on regulating Syk, PLCγ2, and PI3K phosphorylation was explored. Our findings demonstrate that SA treatment, compared to the control group, significantly diminished the phosphorylation of Syk, PLCγ2, and PI3K, as well as the downstream kinase AKT and mitogen-activated protein kinases (MAPKs), following CRP induction (Figure 3). These findings indicate that SA plays an essential role in regulating Syk, PLCγ2, PI3K, AKT, and extracellular signal-regulated kinase (ERK) phosphorylation without displaying selectivity toward specific signal transduction pathways.

2.4. SA prevents In Vivo Thrombosis, While Having No Impact on Hemostasis

To explore the influence of SA on arterial thrombus generation, a mouse model of FeCl3-promoted carotid artery thrombosis was developed. Thrombus formation was assessed using a 10% (460 mM) FeCl3 solution. After FeCl3 application, carotid occlusion was observed at a mean time of 9.73 ± 2.23 min in the control group. However, SA therapy increased the carotid occlusion time to 15.78 ± 2.72 min at a concentration of 50 mg/kg BW or 20.83 ± 2.64 min at a concentration of 100 mg/kg BW compared to that in the positive control (27.98 ± 2.91 min) at an ASA concentration of 100 mg/kg BW (Figure 4A,B). To further evaluate the impact of oral SA administration on hemostatic function, the tail bleeding time was assessed as the timepoint of ceased bleeding after tail amputation. Our findings demonstrated no statistically significant differences in the value of this parameter between two studied groups (Figure 4C). Furthermore, the volume of blood collected from an amputation site, stratified according to hemoglobin content, did not differ between the groups. However, oral administration of ASA at a dose of 100 mg/kg significantly elevated the bleeding time and increased hemoglobin levels (Figure 4D). These findings indicate that SA plays an important role in arterial thrombosis in vivo, while not interfering with the processes of hemostasis.

2.5. Phytochemical Profiling of SA

UHPLC-MS/MS analysis is widely utilized because it has high sensitivity and resolution and facilitates the systematic profiling of active components presents within plants [14,15]. In this study, Sinomenium acutum extract was analyzed via UHPLC-MS/MS to identify major components. Through a comparison of the retention time (Rt) and mass spectra with reference standards, we identified eleven phytochemicals predominantly present in the extract. These include higenamine, acutumidine, acutumine, sinomenine, gelsemine, magnoflorine, scopoletin, columbamine (or jatrorrhizine), palmatine, syringin, and eleutheroside E, all of which are found in Sinomenium acutum (Table 1). Figure 5 illustrates the base peak chromatograms and the extracted ion chromatograms of these identified phytochemicals in Sinomenium acutum.

3. Discussion

For this study, we evaluated the effects of SA ethanol extract on platelet function including antithrombotic effects. Our findings revealed that SA exhibited a protective effect against platelet aggregation and activation and improved platelet-thrombus formation via the GPVI-mediated platelet signalosome. Previous studies have primarily focused on the antioxidant, anti-inflammatory, analgesic, anti-allergic, immunosuppressive, anti-tumor, liver-protective, and other effects of SA. Clinical use of SA therapy has mainly been documented in relation to rheumatoid arthritis, ankylosing spondylitis, and other diseases [10,11]. However, this study is the first to describe the antiplatelet effect of SA on GPVI-mediated platelet aggregation and thrombus formation.
To investigate the underlying mechanism, we investigated GPVI-mediated intracellular Ca2+ mobilization, granular secretion, and fibrinogen binding to integrin αIIbβ3 (JON/A). Our findings demonstrated that SA extract markedly inhibited intracellular Ca2+ activation, ATP secretion, P-selectin exposure, and integrin αIIbβ3 stimulation. Targeting the collagen receptor GPVI has been shown to be an effective approach to reducing thrombosis while maintaining hemostasis [18]. Furthermore, clinical trials investigating the humanized anti-GPVI Fab fragment (ACT01) and the dimeric GPVI-Fc fusion protein (Revacept) demonstrated their inhibitory effects on the interaction between platelets and collagen without affecting general hemostasis [19,20]. These findings suggest that targeting GPVI could be a promising approach for antithrombotic treatment. In the present study, both the biochemical and in vivo results demonstrated that SA treatment could effectively prevent GPVI-mediated platelet aggregation and thrombus formation without increasing the risk of bleeding. The inhibitory effects of SA extract on platelet aggregation, activation, degranulation, and thrombus formation might be based on the inhibitory effects of the GPVI-mediated signaling pathway during cell activation.
The binding of the GPVI to immobilized collagen initiates the adhesion of flowing platelets to the subendothelial extracellular matrix and, thereby, enables the signaling pathway, which is initiated by the Src-family-kinase-mediated phosphorylation of tyrosine residues associated with the immunoreceptor tyrosine-based activation motif containing FcRγ chains [3]. Subsequently, phospholipase Cγ2 (PLCγ2) is activated by the signaling cascades involved in the recruitment and activation of spleen tyrosine kinase (Syk), the SH2 domain-containing leukocyte protein of 76 kDa (SLP-76), Proto-oncogene vav (Vav1), phosphatidylinositol 3-kinase (PI3K), and Bruton’s tyrosine kinase (Btk). The tyrosine phosphorylation-based activation of PLCγ2 eventually leads to intracellular Ca2+ accumulation, a marker of platelet activation and thrombus formation [7,8]. We observed that SA extract significantly inhibited the increase in phosphorylation of Syk, PLCγ2, PI3K, and AKT induced by CRP [21,22,23]. It has been demonstrated that the phosphorylation of PI3K and AKT is highly expressed in platelets, and these are key signaling pathways for GPVI downstream activation induced by collagen [24,25,26]. The PI3K and AKT pathways are downstream of Src family kinases and are the integral part of platelet activation by influencing intracellular Ca2+ mobilization, granular secretion, and platelet aggregation [25,26,27]. Thus, our findings suggest that the inhibitory effects of SA extract on the phosphorylation of Syk, PLCγ2, PI3K, and AKT pathways comprise an efficient and safe antiplatelet and antithrombotic strategy for GPVI-mediated platelet functions.
The FeCl3-promoted vascular injury model is commonly used to assess antithrombotic activity and has been well established for evaluating in vivo antithrombotic effects [2]. Tseng et al. demonstrated that FeCl3 accesses the endothelium through small vesicles via an endocytic–exocytic route, resulting in complete endothelial denudation [28]. This process exposes the subendothelial matrix (collagen) and leads to arterial thrombus formation with platelet activation and fibrin formation, which can be attenuated using antiplatelet agents [29]. In our study, we found that SA treatment significantly increased vascular occlusion times in mice by suppressing platelet activation without expanding the bleeding time compared to vehicle treatment. In addition, because FeCl3-induced injury can disrupt the endothelium, our findings further suggest that SA is important for regulating endothelial cells in arterial thrombosis. Interestingly, SA treatment did not affect the hemostatic function at the site of tail transaction [30]. Noting that the tail bleeding time may not be a reliable analysis of platelet contribution to hemostatic function, we also observed no increased bleeding from the surgery site during the FeCl3-induced injury arterial thrombosis study. Additionally, depending on the activities and concentrations of herbal extracts, results might differ [31]. We also observed that SA did not differ in the coagulation parameter compared with the control group (Supplemental Table S1). Consequently, unless SA concentrations exceed threshold concentration levels, there is still a chance that SA treatment will result in a reduction in antiplatelets without anticoagulation properties. Therefore, our findings suggest that SA is a potent natural candidate for alleviating platelet-related cardiovascular diseases.
Previous studies have reported that SA inhibits inflammation by suppressing nuclear factor kappa B activation in a rat model of endotoxin-induced uveitis [32]. In addition, sinomenine, the main component of SA, has been widely used in treating autoimmune diseases, as reported by numerous pharmacological studies [10]. These findings suggest that SA may have anti-inflammatory effects that can help prevent cardiovascular diseases such as atherosclerosis and stroke. Therefore, while sinomenine could be used as a principal compound for the design of SA-based antiplatelet agents, further research is needed to fully understand its effect on future drug development.
In conclusion, our findings suggest that SA treatment may have antiplatelet and antithrombotic effects by suppressing GPVI signaling. Therefore, SA can serve as a foundation for the development of new antiplatelet drugs to treat patients with cardiovascular diseases.

4. Materials and Methods

4.1. Reagent

Human thrombin, PGE1, rhodamine-phalloidin, dimethyl sulfoxide (DMSO), ADP, fibrinogen, human fibrinogen, ferric chloride (FeCl3), Acetylsalicylic acid (ASA), carboxymethylcellulose (CMC), and all the reagents were purchased from Sigma (St. Louis, MO, USA). Equine tendon collagen (type I) and ATP luciferin/luciferase reagent were obtained from Chrono-log (Havertown, PA, USA). CRP was obtained from Dr Richard Farndale (Department of Biochemistry, University of Cambridge, UK). Phycoerythrin (PE)-conjugated isotype control IgGs, rat monoclonal antibodies against mouse P-selectin, activated αIIbβ3 (JON/A) were from Emfret Analytics (Eibelstadt, Germany). Antibodies against phospho-Syk at Tyr525/526 (Cat# 2710S), phospho-PLCγ2 at Tyr1217 (Cat# 3871S), phospho-PI3K p85α/β at Tyr458/p55α/γ at Tyr199 (Cat# 4228S), phospho-Akt at Ser473 (Cat# 9271S), phospho-ERK at Thr202/Tyr204 (Cat# 4337S), Total Syk (Cat# 12358S), Total PLCγ2 (Cat# 3872S), Total PI3K p85 (Cat# 4249S), Total Akt (Cat# 9272S), Total ERK (Cat# 9102S), and β-actin (Cat# 4967S) were obtained from Cell Signaling (Danvers, MA, USA). Monoclonal antibodies against phospho-integrin β3 at Tyr 759 and Total integrin β3 were obtained from Santa Cruz (Santa Cruz, CA, USA). Calcium dye (FLIPR Calcium Assay kit) was from Molecular Devices (Sunnyvale, CA, USA).

4.2. Herbal Medicine Preparation

The SA was received from Omniherb Co., Ltd. (Yerongcheon, Korea). To prepare the extract, the dried SA (100 g) was mixed into 1000 mL of 30% ethyl alcohol in an extractor (Gyeongseo Extractor Cosmos-600, Inchon, Korea) for 12 h. The obtained extract then underwent filtering through a 150 μm standard test sieve (Retsch, Hann, Germany) and subsequent freeze drying, resulting in a concentration of 4.3%. The lyophilized powder was then dissolved in 0.01% DMSO, finally reaching a concentration of 100 mg/mL.

4.3. Animals

Male mice of the wild-type C57BL/6 strain, aged 6–8 weeks and weighing 18–22 g, were received from DooYeol Biotech (Seoul, Korea) and allowed to acclimate for one week. There were a total of four random groups, with ten animals in each. They were as follows: (1) a vehicle group, receiving 0.5% low-viscosity CMC orally; (2) a low-dose SA group, with 50 mg/kg body weight (BW); (3) a high-dose SA group, administered 100 mg/kg BW; and (4) an ASA group, receiving 100 mg/kg BW. They were maintained under monitored conditions of temperature and humidity, with a 12/12 h light/dark cycle. The animals were treated in accordance with the National Animal Welfare Law of Korea, and all the performed animal experiments (reference number #23-035) were conducted in compliance with the Korea Institute of Oriental Medicine (KIOM, Daegu, Korea) Care Committee guidelines.

4.4. Platelet Preparation

Whole-blood samples were obtained from mice with acid-citrate-dextrose (ACD) buffer (Sigma). To collect platelet-rich plasma (PRP), the whole blood was centrifuged at 300× g for 20 min with no brake applied, and prostaglandin E1 (0.5 µM) was added to prevent platelet activation. The PRP was then recentrifuged at 700 g for 4 min to obtain the platelet pellet. The isolated pellet was suspended in 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)-Tyrode buffer (5 mM HEPES/NaOH, pH 7.3, 5 mM glucose, 136 mM NaCl, 12 mM NaHCO3, 2.7 mM KCl) containing 10% ACD and recentrifuged at 700 g for 5 min. The resulting final pellet was counted using a hemocytometer and adjusted to a concentration of 3 × 108 platelets/mL with HEPES-Tyrode buffer [33,34,35].

4.5. Platelet Aggregation and ATP Secretion

The platelets were placed in modified HEPES-Tyrode buffer and then grown with either 0.01% DMSO or one of three concentrations of SA (50, 100, or 200 µg/mL) for 10 min at 37 °C. They were then activated via various agonists, including collagen (1 µg/mL), CRP (0.5 µg/mL), thrombin (0.05 U/mL), U46619 (3 µM), or ADP (2.5 µM). In some experiments, PRP was preincubated with either 0.01% DMSO or one of three concentrations of SA (50, 100, or 200 µg/mL) for 10 min at 37 °C. They were then stimulated with collagen (1 µg/mL) or CRP (0.5 µg/mL). In the case of ADP-facilitated aggregation, human FG (30 µg/mL) was added to the platelet suspension prior to ADP induction. Platelet aggregation was determined with a 4-channel platelet Lumi-aggregometer (Chrono-Log Corp., Havertown, PA, USA) at 37 °C with stirring at 1000 rpm. Platelet secretion was controlled by measuring that of ADP/ATP through the addition of luciferin/luciferase reagent (Chrono-log) to the platelet suspension [36,37].

4.6. Flow Cytometric Analysis

The rinsed platelets were treated with either 0.01% DMSO or one of three concentrations of SA (50, 100, or 200 µg/mL) for 10 min at 37 °C. They were then processed with 0.5 μg/mL of CRP for five minutes at 37 °C and incubated with phycoerythrin-conjugated antibodies against P-selectin or induced αIIbβ3 integrin (JON/A) for 15 min. The cells were then evaluated using flow cytometry (Gallios, Beckman Coulter, Bera, CA, USA).

4.7. Ca2+ Mobilization

The rinsed platelets (1 × 108/mL) were immersed in HEPES-Tyrode buffer (pH 7.4) without CaCl2 and subjected to treatment with either 0.01% DMSO or one of three concentrations of SA (50, 100, or 200 µg/mL) for 10 min at 37 °C. The cells were then stained with a Ca2+ dye (FLIPR Calcium 5 Assay kit) for 30 min at 37 °C in the dark and then stimulated with CRP (0.2 µg/mL). Cytosolic Ca2+ levels were determined with a spectrofluorometer (Spectramax I3, Molecular Devices) with an excitation wavelength of 485 nm and an emission of 525 nm. Ca2+ mobilization was evaluated by measuring the area under the curve and expressed as a relative fluorescence unit.

4.8. Immunoblotting

Mouse platelets were preincubated with three different concentrations of SA (50, 100, or 200 µg/mL) for 10 min and then stimulated with 0.5 µg/mL CRP for 5 min under constant stirring at 1000 rpm in an aggregometer. To measure the phosphorylation levels of kinases, platelets were lysed in lysis buffer. The lysed platelets were then sonicated. An equal amount of protein (30 µg) was electrophoresed under reduced conditions and subsequently transferred to polyvinylidene difluoride membranes (Millipore, Billerica, MA, USA). The immunoblot was blocked with TBS-T buffer containing 5% BSA for 1 h and incubated overnight at 4 °C with different primary antibodies. After being washed 4 times for 10 min each with TBS-T buffer, the blots were probed with a Horseradish peroxidase (HRP)-conjugated secondary antibody (1:5000, Santa CruZ Biotechnology, Santa Cruz, CA, USA, sc-2004 and sc-2005) for 1 h at room temperature, and the membranes were visualized using enhanced chemiluminescence. The band density was quantified via densitometry using ImageJ software (v1.52a). Phosphorylation levels of kinases were determined by normalizing the density of antibodies against phosphorylated kinases to that of antibodies against total kinases.

4.9. FeCl3-Induced In Vivo Thrombosis and Tail Bleeding Time

Mice were administered 0.5% low-viscosity CMC or SA (50 or 100 mg/kg BW) or ASA (100 mg/kg BW) orally once a day for seven days. On the final day, the administration was performed 30 min prior to the experiments. Following the last administration, the mice were anesthetized with 2.5% isoflurane in an oxygen mixture. The left carotid artery was isolated, and a filter paper (2 mm in diameter) soaked in 10% (460 mM) FeCl3 was placed over the artery for two minutes. Blood flow was then monitored until 10 min after blood occlusion using a blood flowmeter (AD Instruments). For the bleeding assay, one hour after the last administration, mice were anaesthetized, and the tail bleeding assay was performed as previously described [34].

4.10. Phytochemical Profiling of Sinomenium acutum with Ultra-High-Performance Liquid Chromatography–Tandem Mass Spectrometry (UHPLC–MS/MS)

The phytochemical components of Sinomenium acutum were identified as depicted above [16,17] and compared with the reference retention time and mass spectrum. The latter included higenamine, gelsemine, magnoflorine, scopoletin, columbamine, jatrorrhizine, palmatine, syringin, and eleutheroside E, which were purchased from TargetMol (Wellesley Hills, MA, USA). UHPLC–MS/MS analysis was performed with a Dionex UltiMate 3000 system coupled with a Thermo Q-Exactive mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA). The dried powder of Sinomenium acutum extract was added to 100% MeOH to attain a concentration of 20 mg/mL. Chromatographic separation was performed using an Acquity BEH C18 column (100 × 2.1 mm, 1.7 µm) with 0.1% formic acid in water and acetonitrile. The gradient eluent condition for UHPLC and the details for MS/MS were incorporated, as previously shown [38]. Data acquisition and processing were carried out withXcalibur and TraceFinder 5.1 software systems (Thermo Fisher Scientific).

4.11. Statistical Analysis

Data analyses were implemented with GraphPad Prism 9.5.1. An analysis of variance followed by Tukey’s or Dunnett’s test was applied for the comparison of multiple groups, while Student’s t-test was employed for that between two groups. A p-value of <0.05 was regarded statistically significant.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ph17010006/s1, Figure S1: Role of Sinomenium acutum (SA) in platelet aggregation following collagen and CRP stimulation. Table S1: Coagulation parameters in SA treatment.

Author Contributions

Y.-J.K. designed and performed research, and wrote the manuscript; T.I.K. performed research and wrote the manuscript; A.L. performed UHPLC-MS/MS and wrote the manuscript; K.K. initiated and designed research, provided important data, and wrote the manuscript; Y.-H.H. initiated and designed research, and wrote the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This work was funded by the Korean Institute of Oriental Medicine (KSN2212020).

Institutional Review Board Statement

All experimental animal procedures were approved by the Institutional Animal Care and Use Committee of Korea Institute of Oriental Medicine (KIOM-23-035) and performed in accordance with their guidelines.

Informed Consent Statement

Not applicable.

Data Availability Statement

All the data supporting the results were shown in the paper, and can be obtained from the corresponding author.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Zhou, Y.; Zhang, D.; Tan, P.; Xian, B.; Jiang, H.; Wu, Q.; Huang, X.; Zhang, P.; Xiao, X.; Pei, J. Mechanism of platelet activation and potential therapeutic effects of natural drugs. Phytomedicine 2023, 108, 154463. [Google Scholar] [CrossRef]
  2. Furie, B.; Furie, B.C. Mechanisms of thrombus formation. N. Engl. J. Med. 2008, 359, 938–949. [Google Scholar] [CrossRef]
  3. Nieswandt, B.; Watson, S.P. Platelet-collagen interaction: Is gpvi the central receptor? Blood 2003, 102, 449–461. [Google Scholar] [CrossRef]
  4. Lowell, C.A. Src-family and syk kinases in activating and inhibitory pathways in innate immune cells: Signaling cross talk. Cold Spring Harb. Perspect. Biol. 2011, 3, a002352. [Google Scholar] [CrossRef]
  5. Watson, S.P.; Asazuma, N.; Atkinson, B.; Berlanga, O.; Best, D.; Bobe, R.; Jarvis, G.; Marshall, S.; Snell, D.; Stafford, M.; et al. The role of itam- and itim-coupled receptors in platelet activation by collagen. Thromb. Haemost. 2001, 86, 276–288. [Google Scholar]
  6. Dütting, S.; Bender, M.; Nieswandt, B. Platelet gpvi: A target for antithrombotic therapy?! Trends Pharmacol. Sci. 2012, 33, 583–590. [Google Scholar] [CrossRef]
  7. Munnix, I.C.; Strehl, A.; Kuijpers, M.J.; Auger, J.M.; van der Meijden, P.E.; van Zandvoort, M.A.; oude Egbrink, M.G.; Nieswandt, B.; Heemskerk, J.W. The glycoprotein vi-phospholipase cgamma2 signaling pathway controls thrombus formation induced by collagen and tissue factor in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 2673–2678. [Google Scholar] [CrossRef]
  8. Varga-Szabo, D.; Braun, A.; Nieswandt, B. Calcium signaling in platelets. J. Thromb. Haemost. 2009, 7, 1057–1066. [Google Scholar] [CrossRef]
  9. Nurden, A.T. Clinical significance of altered collagen-receptor functioning in platelets with emphasis on glycoprotein vi. Blood Rev. 2019, 38, 100592. [Google Scholar] [CrossRef]
  10. Ding, C.; Li, Y.; Sun, Y.; Wu, Y.; Wang, F.; Liu, C.; Zhang, H.; Jiang, Y.; Zhang, D.; Song, X. Sinomenium acutum: A comprehensive review of its botany, phytochemistry, pharmacology and clinical application. Am. J. Chin. Med. 2022, 50, 1219–1253. [Google Scholar] [CrossRef]
  11. Zhao, X.X.; Peng, C.; Zhang, H.; Qin, L.P. Sinomenium acutum: A review of chemistry, pharmacology, pharmacokinetics, and clinical use. Pharm. Biol. 2012, 50, 1053–1061. 47. [Google Scholar] [CrossRef]
  12. Stefanini, L.; Roden, R.C.; Bergmeier, W. Caldag-gefi is at the nexus of calcium-dependent platelet activation. Blood 2009, 114, 2506–2514. [Google Scholar] [CrossRef]
  13. Berlanga, O.; Bobe, R.; Becker, M.; Murphy, G.; Leduc, M.; Bon, C.; Barry, F.A.; Gibbins, J.M.; Garcia, P.; Frampton, J.; et al. Expression of the collagen receptor glycoprotein vi during megakaryocyte differentiation. Blood 2000, 96, 2740–2745. [Google Scholar] [CrossRef]
  14. Zou, Y.T.; Long, F.; Wu, C.Y.; Zhou, J.; Zhang, W.; Xu, J.D.; Zhang, Y.Q.; Li, S.L. A dereplication strategy for identifying triterpene acid analogues in poria cocos by comparing predicted and acquired uplc-esi-qtof-ms/ms data. Phytochem. Anal. 2019, 30, 292–310. [Google Scholar] [CrossRef]
  15. Jang, S.; Lee, A.; Hwang, Y.-H. Qualitative profiling and quantitative analysis of major constituents in jinmu-tang by uhplc-q-orbitrap-ms and uplc-tq-ms/ms. Molecules 2022, 27, 7887. [Google Scholar] [CrossRef]
  16. Wang, Y.; Gao, X.; Wang, J.; Tang, M.; Yu, B.; Wang, Z.; Cao, L.; Chen, X.; Qian, M.; Wang, S.; et al. Identification and characterization of major alkaloid from sinomenium acutum stem and their metabolites after oral administration in rat plasma, urine, bile and feces based on uplc-q-tof/ms. J. Pharm. Biomed. Anal. 2022, 220, 115005. [Google Scholar] [CrossRef]
  17. Huang, Y.-F.; He, F.; Wang, C.-J.; Xie, Y.; Zhang, Y.-Y.; Sang, Z.; Qiu, P.; Luo, P.; Xiao, S.-Y.; Li, J.; et al. Discovery of chemical markers for improving the quality and safety control of Sinomenium acutum stem by the simultaneous determination of multiple alkaloids using uhplc-qqq-ms/ms. Sci. Rep. 2020, 10, 14182. [Google Scholar] [CrossRef]
  18. McFadyen, J.D.; Schaff, M.; Peter, K. Current and future antiplatelet therapies: Emphasis on preserving haemostasis. Nat. Rev. Cardiol. 2018, 15, 181–191. [Google Scholar] [CrossRef]
  19. Lebozec, K.; Jandrot-Perrus, M.; Avenard, G.; Favre-Bulle, O.; Billiald, P. Design, development and characterization of act017, a humanized fab that blocks platelet’s glycoprotein vi function without causing bleeding risks. mAbs 2017, 9, 945–958. [Google Scholar] [CrossRef]
  20. Ungerer, M.; Rosport, K.; Bultmann, A.; Piechatzek, R.; Uhland, K.; Schlieper, P.; Gawaz, M.; Munch, G. Novel antiplatelet drug revacept (dimeric glycoprotein vi-fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation 2011, 123, 1891–1899. [Google Scholar] [CrossRef]
  21. Law, D.A.; Nannizzi-Alaimo, L.; Ministri, K.; Hughes, P.E.; Forsyth, J.; Turner, M.; Shattil, S.J.; Ginsberg, M.H.; Tybulewicz, V.L.; Phillips, D.R. Genetic and pharmacological analyses of syk function in alphaiibbeta3 signaling in platelets. Blood 1999, 93, 2645–2652. [Google Scholar] [CrossRef]
  22. van Eeuwijk, J.M.; Stegner, D.; Lamb, D.J.; Kraft, P.; Beck, S.; Thielmann, I.; Kiefer, F.; Walzog, B.; Stoll, G.; Nieswandt, B. The novel oral syk inhibitor, bl1002494, protects mice from arterial thrombosis and thromboinflammatory brain infarction. Arterioscler. Thromb. Vasc. Biol. 2016, 36, 1247–1253. [Google Scholar] [CrossRef]
  23. Braselmann, S.; Taylor, V.; Zhao, H.; Wang, S.; Sylvain, C.; Baluom, M.; Qu, K.; Herlaar, E.; Lau, A.; Young, C.; et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J. Pharmacol. Exp. Ther. 2006, 319, 998–1008. [Google Scholar] [CrossRef]
  24. Senis, Y.A.; Atkinson, B.T.; Pearce, A.C.; Wonerow, P.; Auger, J.M.; Okkenhaug, K.; Pearce, W.; Vigorito, E.; Vanhaesebroeck, B.; Turner, M.; et al. Role of the p110delta pi 3-kinase in integrin and itam receptor signalling in platelets. Platelets 2005, 16, 191–202. [Google Scholar] [CrossRef]
  25. Lian, L.; Wang, Y.; Draznin, J.; Eslin, D.; Bennett, J.S.; Poncz, M.; Wu, D.; Abrams, C.S. The relative role of plcbeta and pi3kgamma in platelet activation. Blood 2005, 106, 110–117. [Google Scholar] [CrossRef]
  26. Adam, F.; Kauskot, A.; Rosa, J.P.; Bryckaert, M. Mitogen-activated protein kinases in hemostasis and thrombosis. J. Thromb. Haemost. 2008, 6, 2007–2016. [Google Scholar] [CrossRef] [PubMed]
  27. Gilio, K.; Munnix, I.C.; Mangin, P.; Cosemans, J.M.; Feijge, M.A.; van der Meijden, P.E.; Olieslagers, S.; Chrzanowska-Wodnicka, M.B.; Lillian, R.; Schoenwaelder, S.; et al. Non-redundant roles of phosphoinositide 3-kinase isoforms alpha and beta in glycoprotein vi-induced platelet signaling and thrombus formation. J. Biol. Chem. 2009, 284, 33750–33762. [Google Scholar] [CrossRef] [PubMed]
  28. Tseng, M.T.; Dozier, A.; Haribabu, B.; Graham, U.M. Transendothelial migration of ferric ion in fecl3 injured murine common carotid artery. Thromb. Res. 2006, 118, 275–280. [Google Scholar] [CrossRef]
  29. Eckly, A.; Hechler, B.; Freund, M.; Zerr, M.; Cazenave, J.P.; Lanza, F.; Mangin, P.H.; Gachet, C. Mechanisms underlying fecl3-induced arterial thrombosis. J. Thromb. Haemost. 2011, 9, 779–789. [Google Scholar] [CrossRef]
  30. Kurz, K.D.; Main, B.W.; Sandusky, G.E. Rat model of arterial thrombosis induced by ferric chloride. Thromb. Res. 1990, 60, 269–280. [Google Scholar] [CrossRef]
  31. Chukwumah, Y.; Walker, L.; Vogler, B.; Verghese, M. Changes in the phytochemical composition and profile of raw, boiled, and roasted peanuts. J. Agric. Food Chem. 2007, 55, 9266–9273. [Google Scholar] [CrossRef]
  32. Kim, T.W.; Han, J.M.; Han, Y.K.; Chung, H. Anti-inflammatory effects of Sinomenium acutum extract on endotoxin-induced uveitis in lewis rats. Int. J. Med. Sci. 2018, 15, 758–764. [Google Scholar] [CrossRef]
  33. Kim, Y.J.; Kim, T.I.; Kim, K. An optimized herbal medicine containing Scutellaria baicalensis Georgi, Alisma orientale Juzepzuk, and Atractylodes japonica Koidzumi has potent antiplatelet and antithrombotic activities. J. Tradit. Complement. Med. 2023, 13, 285–296. [Google Scholar] [CrossRef]
  34. Kim, T.I.; Kim, Y.J.; Kim, K. Extract of seaweed inhibits integrin αiibβ3-induced outside-in signaling and arterial thrombosis. Front. Pharmacol. 2021, 12, 685948. [Google Scholar] [CrossRef]
  35. Amirou, A.; Bnouham, M.; Legssyer, A.; Ziyyat, A.; Aziz, M.; Berrabah, M.; Mekhfi, H. Effects of root bark extract on platelet aggregation, bleeding time, and plasmatic coagulation: And experiments. Evid.-Based Complement. Altern. Med. 2018, 2018, 7313517. [Google Scholar] [CrossRef]
  36. Endale, M.; Lee, W.M.; Kamruzzaman, S.M.; Kim, S.D.; Park, J.Y.; Park, M.H.; Park, T.Y.; Park, H.J.; Cho, J.Y.; Rhee, M.H. Ginsenoside-rp1 inhibits platelet activation and thrombus formation via impaired glycoprotein vi signalling pathway, tyrosine phosphorylation and mapk activation. Br. J. Pharmacol. 2012, 167, 109–127. [Google Scholar] [CrossRef]
  37. Kamruzzaman, S.M.; Endale, M.; Oh, W.J.; Park, S.C.; Kim, K.S.; Hong, J.H.; Kwak, Y.S.; Yun, B.S.; Rhee, M.H. Inhibitory effects of aqueous extract on agonist-induced platelet activation and thrombus formation involves mitogen-activated protein kinases. J. Ethnopharmacol. 2010, 130, 614–620. [Google Scholar] [CrossRef]
  38. Hwang, Y.H.; Jang, S.A.; Kim, T.; Ha, H. Anti-osteoporotic and anti-adipogenic effects of rhus chinensis nutgalls in ovariectomized mice fed with a high-fat diet. Planta Med. 2019, 85, 1128–1135. [Google Scholar] [CrossRef]
Pharmaceuticals 17 00006 g001
Figure 1. The suppressing effect of Sinomenium acutum (SA) on platelet aggregation and adenosine triphosphate (ATP) secretion activated by different agonists. Platelets were preincubated with the different characteristics of the solutions of SA (50, 100, and 200 µg/mL) for 10 min at 37 °C. Subsequently, they were induced by 1 µg/mL collagen (A), 0.5 µg/mL collagen-related peptide (CRP) (B), 0.05 U/mL thrombin (C), 3 µM U46619 (D), and 2.5 µM adenosine diphosphate (ADP) (E). In ATP secretion, cleansed platelets’ surfaces were prepared with the various concentrations of SA (50, 100, and 200 µg/mL) for 10 min at 37 °C. After the addition of the luciferin/luciferase reagent, platelets were activated with various agonists, then ATP secretion was assessed with a luminometer. PRP was preincubated with either 0.01% DMSO, or one of three concentrations of SA (50, 100, or 200 µg/mL) for 10 min at 37 °C. They were then stimulated with 1 µg/mL collagen (F) or 0.5 µg/mL CRP (G). The data are shown as means ± standard deviations (n = 4). *, p < 0.05; **, p < 0.01; and ***, p < 0.001.
Figure 1. The suppressing effect of Sinomenium acutum (SA) on platelet aggregation and adenosine triphosphate (ATP) secretion activated by different agonists. Platelets were preincubated with the different characteristics of the solutions of SA (50, 100, and 200 µg/mL) for 10 min at 37 °C. Subsequently, they were induced by 1 µg/mL collagen (A), 0.5 µg/mL collagen-related peptide (CRP) (B), 0.05 U/mL thrombin (C), 3 µM U46619 (D), and 2.5 µM adenosine diphosphate (ADP) (E). In ATP secretion, cleansed platelets’ surfaces were prepared with the various concentrations of SA (50, 100, and 200 µg/mL) for 10 min at 37 °C. After the addition of the luciferin/luciferase reagent, platelets were activated with various agonists, then ATP secretion was assessed with a luminometer. PRP was preincubated with either 0.01% DMSO, or one of three concentrations of SA (50, 100, or 200 µg/mL) for 10 min at 37 °C. They were then stimulated with 1 µg/mL collagen (F) or 0.5 µg/mL CRP (G). The data are shown as means ± standard deviations (n = 4). *, p < 0.05; **, p < 0.01; and ***, p < 0.001.
Pharmaceuticals 17 00006 g001
Pharmaceuticals 17 00006 g002
Figure 2. The preventive effect of Sinomenium acutum (SA) on P-selectin exposure, αIIbβ3 integrin stimulation, and Ca2+ mobilization. The binding of anti-P-selectin (A) and anti-activated αIIbβ3 (JON/A) antibodies (B) to platelets was measured as the ratio of the geometric mean fluorescence intensity value of antibodies to that of the control immunoglobulin G. The quantitative data are presented as means ± standard deviations (n = 3). In a Ca2+ mobilization assay, mouse platelets were incubated with a calcium-sensitive dye for 30 min at 37 °C in the dark, and then platelets were induced using 0.5 µg/mL collagen-related peptide (CRP) for 10 min. Intracellular Ca2+ secretion and flow (C) were evaluated and quantified with the area under the curve (arbitrary units). The quantitative data are demonstrated as means ± standard deviations (n = 4). *, p < 0.05; **, p < 0.01; and ***, p < 0.001.
Figure 2. The preventive effect of Sinomenium acutum (SA) on P-selectin exposure, αIIbβ3 integrin stimulation, and Ca2+ mobilization. The binding of anti-P-selectin (A) and anti-activated αIIbβ3 (JON/A) antibodies (B) to platelets was measured as the ratio of the geometric mean fluorescence intensity value of antibodies to that of the control immunoglobulin G. The quantitative data are presented as means ± standard deviations (n = 3). In a Ca2+ mobilization assay, mouse platelets were incubated with a calcium-sensitive dye for 30 min at 37 °C in the dark, and then platelets were induced using 0.5 µg/mL collagen-related peptide (CRP) for 10 min. Intracellular Ca2+ secretion and flow (C) were evaluated and quantified with the area under the curve (arbitrary units). The quantitative data are demonstrated as means ± standard deviations (n = 4). *, p < 0.05; **, p < 0.01; and ***, p < 0.001.
Pharmaceuticals 17 00006 g002
Pharmaceuticals 17 00006 g003
Figure 3. Sinomenium acutum (SA) extract regulates the phosphorylation of spleen tyrosine kinase (Syk), phospholipase Cγ2 (PLCγ2), phosphatidylinositol 3-kinase (PI3K), AKT, and ERK after collagen-related peptide (CRP) stimulation. Mouse platelets were pretreated with various concentrations of SA (50, 100, and 200 µg/mL) and stimulated with 0.5 µg/mL CRP. Equal amounts (30 µg) of cell lysate protein were immunoblotted to determine specific Syk, PLCγ2, PI3K, AKT, and ERK phosphorylation inhibition. The results are shown as blots and graphs. The data are presented as means ± standard deviations (n = 3). #, p < 0.05 and ###, p < 0.001 versus the vehicle control (unstimulated) after Student’s t-test. *, p < 0.05; **, p < 0.01; and ***, p < 0.001 versus the vehicle control (stimulated) after analysis of variance and Tukey’s test.
Figure 3. Sinomenium acutum (SA) extract regulates the phosphorylation of spleen tyrosine kinase (Syk), phospholipase Cγ2 (PLCγ2), phosphatidylinositol 3-kinase (PI3K), AKT, and ERK after collagen-related peptide (CRP) stimulation. Mouse platelets were pretreated with various concentrations of SA (50, 100, and 200 µg/mL) and stimulated with 0.5 µg/mL CRP. Equal amounts (30 µg) of cell lysate protein were immunoblotted to determine specific Syk, PLCγ2, PI3K, AKT, and ERK phosphorylation inhibition. The results are shown as blots and graphs. The data are presented as means ± standard deviations (n = 3). #, p < 0.05 and ###, p < 0.001 versus the vehicle control (unstimulated) after Student’s t-test. *, p < 0.05; **, p < 0.01; and ***, p < 0.001 versus the vehicle control (stimulated) after analysis of variance and Tukey’s test.
Pharmaceuticals 17 00006 g003
Pharmaceuticals 17 00006 g004
Figure 4. Sinomenium acutum (SA) delays FeCl3-induced arterial thrombus formation without causing bleeding. FeCl3-activated arterial thrombus formation was carried out, as shown in Methods. After oral administration of 0.5% low-viscosity carboxymethylcellulose (CMC) and/or SA (50 and 100 mg/kg, body weight) or acetylsalicylic acid (ASA; 100 mg/kg, body weight) once a day for seven days (A,B), 10% FeCl3 was injected into the mouse carotid artery for two minutes, and blood flow traces were controlled until stable occlusion was achieved. In the bleeding time assay, the tails of mice were removed, and the bleeding time (C) was monitored, as demonstrated in Methods. (D) Blood loss during the bleeding time assay was measured by assessing the absorbance at 575 nm for hemoglobin (Hb). The horizontal bars illustrate the median occlusion time (n = 10). #, p < 0.05, ##, p < 0.01 and ###, p < 0.001 versus the vehicle control after Student’s t-test.
Figure 4. Sinomenium acutum (SA) delays FeCl3-induced arterial thrombus formation without causing bleeding. FeCl3-activated arterial thrombus formation was carried out, as shown in Methods. After oral administration of 0.5% low-viscosity carboxymethylcellulose (CMC) and/or SA (50 and 100 mg/kg, body weight) or acetylsalicylic acid (ASA; 100 mg/kg, body weight) once a day for seven days (A,B), 10% FeCl3 was injected into the mouse carotid artery for two minutes, and blood flow traces were controlled until stable occlusion was achieved. In the bleeding time assay, the tails of mice were removed, and the bleeding time (C) was monitored, as demonstrated in Methods. (D) Blood loss during the bleeding time assay was measured by assessing the absorbance at 575 nm for hemoglobin (Hb). The horizontal bars illustrate the median occlusion time (n = 10). #, p < 0.05, ##, p < 0.01 and ###, p < 0.001 versus the vehicle control after Student’s t-test.
Pharmaceuticals 17 00006 g004
Pharmaceuticals 17 00006 g005
Figure 5. Ultra-high-performance liquid chromatography–tandem mass spectrometry examination of Sinomenium acutum. (A) Base peak chromatogram of Sinomenium acutum in positive and negative ion mode. (B) Elicit ion chromatogram of Sinomenium acutum. 1, higenamine; 2, acutumidine; 3, acutumine; 4, sinomenine; 5, gelsemine; 6, magnoflorine; 7, scopoletin; 8, columbamine or jatrorrhizine; 9, palmatine; 10, syringin; 11, eleutheroside E.
Figure 5. Ultra-high-performance liquid chromatography–tandem mass spectrometry examination of Sinomenium acutum. (A) Base peak chromatogram of Sinomenium acutum in positive and negative ion mode. (B) Elicit ion chromatogram of Sinomenium acutum. 1, higenamine; 2, acutumidine; 3, acutumine; 4, sinomenine; 5, gelsemine; 6, magnoflorine; 7, scopoletin; 8, columbamine or jatrorrhizine; 9, palmatine; 10, syringin; 11, eleutheroside E.
Pharmaceuticals 17 00006 g005
Table 1. Phytochemical components of Sinomenium acutum via UHPLC-MS/MS.
Table 1. Phytochemical components of Sinomenium acutum via UHPLC-MS/MS.
NoRt (min)Calculated (m/z)Measured (m/z)Error (ppm)AdductFormulaMS/MS Fragments (m/z)Identification
14.79272.1281272.12830.6464M+HC16H17NO3255, 107, 161Higenamine *
24.93384.1208384.12120.8195M+HC18H22ClNO6305, 341Acutumidine [16]
35.06398.1365398.13691.0345M+HC19H24ClNO6305, 341Acutumine [17]
45.06330.17330.17030.9331M+HC19H23NO4-Sinomenine [17]
55.29323.1754323.17612.0296M+HC20H22N2O2278Gelsemine *
65.69342.17342.17030.9004M+C20H24NO4265, 297Magnoflorine *
76.96193.0495193.04991.9244M+HC10H8O4105, 133, 161Scopoletin *
88.15338.1387338.13890.5175M+C20H20NO4-Columbamine or Jatrorrhizine *
98.89352.1543352.15460.6859M+C21H22NO4336Palmatine *
105.17417.1402417.14122.4101M+HCO2C17H24O9149, 271Syringin *
116.21787.2666787.26811.8373M+HCO2C34H46O18417Eleutheroside E *
*, The comparison with the reference values of retention time and mass spectrum. Rt, retention time.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Kim, Y.-J.; Kim, T.I.; Lee, A.; Kim, K.; Hwang, Y.-H. Sinomenium acutum Modulates Platelet Aggregation and Thrombus Formation by Regulating the Glycoprotein VI-Mediated Signalosome in Mice. Pharmaceuticals 2024, 17, 6. https://doi.org/10.3390/ph17010006

AMA Style

Kim Y-J, Kim TI, Lee A, Kim K, Hwang Y-H. Sinomenium acutum Modulates Platelet Aggregation and Thrombus Formation by Regulating the Glycoprotein VI-Mediated Signalosome in Mice. Pharmaceuticals. 2024; 17(1):6. https://doi.org/10.3390/ph17010006

Chicago/Turabian Style

Kim, Yeon-Ji, Tae In Kim, Ami Lee, Kyungho Kim, and Youn-Hwan Hwang. 2024. "Sinomenium acutum Modulates Platelet Aggregation and Thrombus Formation by Regulating the Glycoprotein VI-Mediated Signalosome in Mice" Pharmaceuticals 17, no. 1: 6. https://doi.org/10.3390/ph17010006

APA Style

Kim, Y. -J., Kim, T. I., Lee, A., Kim, K., & Hwang, Y. -H. (2024). Sinomenium acutum Modulates Platelet Aggregation and Thrombus Formation by Regulating the Glycoprotein VI-Mediated Signalosome in Mice. Pharmaceuticals, 17(1), 6. https://doi.org/10.3390/ph17010006

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop